last modified：2024/11/21
Associate Professor FUKAMI Tatsuki
Faculty, Affiliation
Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences
College and School Educational Field
Laboratory
Drug Metabolism and Toxicology
Academic Background
【Academic background(Doctoral/Master's Degree)】
Kanazawa University Doctor 200809 Completed
【Academic background(Bachelor's Degree)】
Kanazawa University 200403
【Degree】
Ph.D.
Career
Year & Month of Birth
1981/11
Academic Society
The Pharmaceutical Society of Japan
The Japanese Society for the Study of Xenobiotics
International Society for the Study of Xenobiotics
Award
Specialities
Speciality Keywords
Drug metabolism, genetic polymorphism, drug-induced toxicity
Research Themes
A study of human esterases contributing to drug hydrolysis
Role of human CYP2A enzymes on metabolism of drugs, nicotine, and environmental chemicals.
Books
Papers
- In vitro approach to elucidate the relevance of carboxylesterase 2 and N-acetyltransferase 2 to flupirtine-induced liver injury Keigo Konishi, Tatsuki Fukai, Takuo Ogiso, Miki Nakajima Biochemical Pharmacology 155 242-251 2018/07
- Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury Takayuki Amano, Tatsuki Fukami, Takuo Ogiso, Daisuke Hirose, Jeffrey P. Jones, Tsuyoshi Taniguchi, Miki Nakajima. Biochemical Pharmacology 151 69-78 2018/05
- Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs Takuo Ogiso, Tatsuki Fukami, Kenji Mishiro, Keigo Konishi, Jeffrey P. Jones, Miki Nakajima Archives Biochemistry and Biophysics 659 85-92 2018/12
- Quantitative analysis of UDP-glucuronosyltransferase Ugt1a and Ugt2b mRNA expression in the rat liver and small intestine: Sex and strain differences Takaya Kutsukake, Yoichi Furukawa, Kyoko Ondo, Saki Gotoh, Tatsuki Fukami, Miki Nakajima Drug Metabolism and Disposition 47 1 38-44 2019/01
- miR-141-3p commonly regulates human UGT1A isoforms via different mechanisms Naoyuki Tatsumi, Shinsaku Tokumitsu, Masataka Nakano, Tatsuki Fukami, Miki Nakajima Drug metabolism and Pharmacokinetics 33 4 203-210 2018/05
- Role of farnesoid X receptor and bile acids in hepatic tumor development. Shogo Takahashi, Naoki Tanaka, Tatsuki Fukami, Cen Xie, Tomoki Yagai, Donghwan Kim, Thomas J. Velenosi, Tingting Yan, Kristopher W. Krausz, Moshe Levi, Frank J. Gonzalez Hepatology Communications 2 12 1567-1582 2018/12
- Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. Tomohiro Yoshida, Tatsuki Fukami, Takaya Kurokawa, Saki Gotoh, Akifumi Oda, Miki Nakajima European Journal of Pharmaceutical Sciences 111 167-176 2018/01
- Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Yu Yamaura, Naoyuki Tatsumi, Shingo Takagi, Shinsaku Tokumitsu, Tatsuki Fukami, Kazuto Tajiri, Masami Minemura, Tsuyoshi Yokoi, Miki Nakajima Clinical Biochemistry 50 18 1034-1039 2017/12
- Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody Shngo Oda, Yukiko Kato, Masahiko Hatakeyama, Atsushi Iwamura, Tatsuki Fukami, Toshiyuki Kume, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Disposition 45 9 1027-1034 2017/09
- Identification of enzymes responsible for nitrazepam metabolism and toxicity in human Keigo Konishi, Tatsuki Fukami, Saki Gotoh, Miki Nakajima Biochemical Pharmacology 140 150-160 2017/09
- Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway. Shogo Takahashi, Naoki Tanaka, Srujana Golla, Tatsuki Fukami, Kristopher W. Krauz, Marianne A. Polunas, Blair C. Weig, Yusuke Masuo, Cen Xie, Changtao Jiang, Frank J. Gonzalez Toxicological Sciences 158 2 334-346 2017/08
- A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer Masataka Nakano, Tatsuki Fukami, Saki Gotoh, Miki Nakajima Journal of Biological Chemistry 292 12 4873-4884 2017/03
- Hepatic dipeptidyl peptidase-4 controls pharmacokinetics of vildagliptin in vivo Mitsutoshi Asakura, Tatsuki Fukami, Miki Nakajima, Hieaki Fujii, Koichiro Atsuda, Tomoo Itoh, Ryoichi Fujiwara Drug Metabolism and Disposition 45 2 237-245 2017/02
- Cyp2c70 is responsible for the species differences in bile acid metabolism between mice and humans Shogo Takahashi, Tatsuki Fukami, Yusuke Masuo, Chad N. Brocker, Cen Xie, Kristopher W Krauz, C. Roland Wolf, Colin J. Henderson, Frank J Gonzalez Journal of Lipid Research 57 12 2130-1237 2016/12
- Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity Tatsuki Fukami, Azumi Iida, Keigo Konishi, Miki Nakajima Biochemical Pharmacology 116 153-161 2016/09
- Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog Takaya Kurokawa, Tatsuki Fukami, Tomohiro Yoshida, Miki Nakajima Drug Metabolism and Disposition 44 3 409-416 2016/03
- RNA editing modulates human hepatic aryl hydrocarbon receptor expression by creating microRNA recognition sequence Masataka Nakano, Tatsuki Fukami, Saki Gotoh, Masataka Takamiya, Yasuhiro Aoki, Miki Nakajima Journal of Biological Chemistry 291 2 894-903 2016/01
- Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism Shohei Takai, Shingo Oda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Journal of Applied Toxicology 36 1 35-47 2016/01
- Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors Eita Sasaki, Azumi Iida, Shingo Oda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Experimental and Toxicologic Pathology 68 1 27-38 2016/01
- A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Pharmacokinetics 30 1 30-51 2015/02
- Role of human orphan esterases in drug-induced toxicity Tatsuki Fukami Yakugaku-Zasshi 135 11 1235-1244 2015/11
- A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production Kyotaka Muta, Tatsuki Fukami, Miki Nakajima Biochemical Pharmacology 98 4 659-670 2015/12
- P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel Taxane Cabazitazel (Jevtana) in mice Seng Chuan Tang, Anita Kort, Ka Lei Cheung, Hilde Rosing, Tatsuki Fukami, Selvi Durmas, Els Wagenaar, Jeroen Hendrikx, Miki Nakajima, Bart van Vlijmen, Jos Beijnen, Alfred Schinkel Molecular Pharmaceutics 12 10 3714-3723 2015/10
- Single-nucleotide polymorphisms in cytochrome P450 2E1 (CYP2E1) 3'-untranslated region affect the regulation of CYP2E1 by miR-570 Masataka Nakano, Takuya Mohri, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Howard L. McLeod, Miki Nakajima Drug Metabolism and Disposition 43 10 1450-1457 2015/10
- Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases Tatsuki Fukami, Motoki Kariya, Takaya Kurokawa, Azumi Iida, Miki Nakajima European Journal of Pharmaceutical Sciences 78 47-53 2015/10
- Characterization of species differences in tissue diltiazem deacetylation identifies Ces2a as a rat-specific diltiazem deacetylase Takaya Kurokawa, Tstsuki Fukami, Miki Nakajima Drug Metabolism and Disposition 43 8 1218-1225 2015/08
- Carbamazepine-induced liver injury requires CYP3A-mediated metabolism and glutathione depletion in rats Azumi Iida, Eita Sasaki, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Drug Metabolism and Disposition 43 7 958-968 2015/07
- Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast Shingo Oda, Ryoichi Fujiwara, Yuki Kutsuno, Tatsuki Fukami, Tomoo Itoh, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Disposition 43 6 812-828 2015/06
- CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126* Masataka Nakano, Yasunari Fukushima, Shin-ichi Yokota, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Disposition 43 5 703-712 2015/05
- Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice Shohei Takai, Satonori Higuchi, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Journal of Applied Toxicology 35 2 142-151 2015/02
- Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities Kei Takahashi, Yuki Oda, Yasuyuki Toyoda, Tatsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima Pharmaceutical Research 31 3 780-794 2014/03
- An orpham esterase ABHD10 modulates probenecid acyl glucuronidation in human liver Yusuke Ito, Tatsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Dposition 42 12 2109-2116 2014/12
- Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury Kentaro Matsuo, Eita Sasaki, Satonori Higuchi, Shohei Takai, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Yokoi Tsuyoshi Toxicology Letters 224 2 215-224 2014/01
- Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury Azusa Yano, Shingo Oda, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Toxicology Letters 228 1 13-24 2014/07
- Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury Eita Sasaki, Atsushi Iwamura, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Toshiyuki Kume, Tsuyoshi Yokoi Toxicology letters 232 1 79-88 2015/01
- Changes in the expression of miRNAs at the pericantral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs Yu Yamaura, Miki Nakajima, Naoyuki Tatsumi, Shingo Takagi, Tatsuki Fukami, Koichi Tsuneyama, Tsuyoshi Yokoi Toxicology 322 89-98 2014/08
- Retinoid X receptor a in human liver is regulated by miR-34a Yuki Oda, Miki Nakajima, Koichi Tsuneyama, Masataka Takamiya, Yasuhiro Aoki, Tatsuki Fukami, Tsuyoshi Yokoi Biochemical Pharmacology 90 2 179-187 2014/07
- Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase Mai Shimizu, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Drug Metabolism and Disposition 42 7 1103-1109 2014/07
- P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR inhibitor everolimus (Afinitor) in mice Seng Chuan Tang, Rolf W. Sparidans, Ka Lei Cheung, Tatsuki Fukami, Selvi Durmus, Els Wagenaar, Tsuyoshi Yokoi, Bart J.M. van Vlijmen, Jos H. Beijnen, and Alfred H. Schinkel Clinical Cancer Research 20 12 3133-3145 2014/06
- Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes Kei Takahashi, Naoyuki Tatsumi, Tatsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima Drug Metabolism and Pharmacokinetics 29 4 333-340 2014/04
- Involvement of miRNAs in the early phase of halothane-induced liver injury Shinya Endo, Azusa Yano, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Toxicology 319 75-84 2014/05
- Indiplon is hydrolyzed by arylacetamide deacetylase in human liver Mai Shimizu, Tatsuki Fukami, Yusuke Ito, Takaya Kurokawa, Motoki Kariya, Miki Nakajima, Tsuyoshi Yokoi Drug Metabolism and Disposition 42 4 751-758 2014/04
- Epigenetic regulation of the tissue-specific expression of human UDP-gucuronosyltransferase (UGT) 1A10 Shingo Oda, Tstsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima Biochemical Pharmacology 87 4 660-667 2014/02
- Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of non steroidal anti-inflammatory drugs Taishi Miyashita, Kento Kimura, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Drug Metabolism and Disposition 42 1 1-8 2014/01
- N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity Kyotaka Muta, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Biochemical Pharmacology 87 2 352-359 2014/01
- A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism Eita Sasaki, Kentaro Matsuo, Azumi iida, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi Toxicological Sciences 136 1 250-263 2013/11
- Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney Shingo Oda, Tatsuki Fukami, Tsuyoshi, Yokoi, Miki Nakajima Drug Metabolism and Disposition 41 10 1738-1743 2013/10
- Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Yukiko Kato, Takeshi Izukawa, Shingo Oda, Tatsuki Fukami, Mosche Finel, Tsuyoshi Yokoi, and Miki Nakajima DRUG METABOLISM AND DISPOSITION 41 7 1389-1397 2013/07
- Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Kei Takahashi, Shin-ichi Yokota, Naoyuki Tatsumi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima TOXICOLOGY AND APPLIED PHARMACOLOGY 272 1 154-160 2013/05
- Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. Ryota Higuchi, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 41 6 1220-1230 2013/06
- The emerging role of human esterases. Tatsuki Fukami and Tsuyoshi Yokoi Drug Metab Pharmacokinet 27 5 466-477 2012/09
- Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Yuki Kobayashi, Tatsuki Fukami, Ryota Higuchi, Miki Nakajima, and Tsuyoshi Yokoi BIOCHEMICAL PHARMACOLOGY 84 9 1196-1206 2012/11
- Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Satonori Higuchi, Azusa Yano, Shohei Takai, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGICAL SCIENCES 130 1 4-16 2012/11
- Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. Taishi Miyashita, Yasuyuki Toyoda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi J Toxicol Sci 37 5 931-942 2012/11
- Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Yukitaka Yoshikawa, Taishi Miyashita, Satonori Higuchi, Koichi Tsuneyama, Shinya Endo, Tohru Tsukui, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY AND APPLIED PHARMACOLOGY 264 1 42-50 2012/10
- Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. Shinya Endo, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi Drug Metab Pharmacokinet 27 6 621-630 2012/06
- Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. Shingo Oda, Miki Nakajima, Masahiko Hatakeyama, Tatsuki Fukami, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 40 8 1620-1627 2012/08
- Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Yuki Kobayashi, Tatsuki Fukami, Mai Shimizu, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 40 6 1080-1084 2012/06
- A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. Mai Shimizu, Tatsuki Fukami, Yuki Kobayashi, Masataka Takamiya, Yasuhiro Aoki, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 40 6 1183-1190 2012/06
- Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. Komphimol Kulthong, Rawiwan Maniratanachote, Yuki Kobayashi, Tatsuki Fukami, and Tsuyoshi Yokoi XENOBIOTICA 42 9 854-862 2012/09
- Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Yuki Oda, Miki Nakajima, Takuya Mohri, Masataka Takamiya, Yasuhiro Aoki, Tatsuki Fukami, and Tsuyoshi Yokoi TOXICOLOGY AND APPLIED PHARMACOLOGY 260 3 222-231 2012/05
- Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. Atsushi Iwamura, Tatsuki Fukami, Ryota Higuchi, Miki Nakajima, and Tsuyoshi Yokoi JOURNAL OF BIOLOGICAL CHEMISTRY 287 12 9240-9249 2012/06
- Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Azusa Yano, Satonori Higuchi, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY 293 1-3 107-114 2012/05
- Th2 cytokine-mediated methimazole-induced acute liver injury in mice. Masanori Kobayashi, Satonori Higuchi, Mika Ide, Satomi Nishikawa, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi JOURNAL OF APPLIED TOXICOLOGY 32 10 823-833 2012/05
- Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Yuki Kobayashi, Tatsuki Fukami, Akinori Nakajima, Akinobu Watanabe, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 40 4 671-679 2012/04
- Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. Yu Yamaura, Miki Nakajima, Shingo Takagi, Tatsuki Fukami, Koichi Tsuneyama, and Tsuyoshi Yokoi PLoS One 7 2 e30250 2012/02
- Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Yasuyuki Toyoda, Shinya Endo, Koichi Tsuneyama, Taishi Miyashita, Azusa Yano, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGICAL SCIENCES 126 1 16-27 2012/03
- Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their con Yukiko Kato, Miki Nakajima, Shingo Oda, Tatsuki Fukami, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 40 2 240-248 2012/02
- Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. Satonori Higuchi, Masanori Kobayashi, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi JOURNAL OF APPLIED TOXICOLOGY 32 10 815-822 2012/02
- Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. Shingo Oda, Miki Nakajima, Yasuyuki Toyoda, Tatsuki Fukami, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 39 11 2057-2065 2011/11
- Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Akinori Nakajima, Tatsuki Fukami, Yuki Kobayashi, Akinobu Watanabe, Miki Nakajima, and Tsuyoshi Yokoi BIOCHEMICAL PHARMACOLOGY 82 11 1747-1756 2011/11
- PPARa is regulated by miR-21 and miR-27b in human liver. Katsuhiko Kida, Miki Nakajima, Takuya Mohri, Yuki Oda, Shingo Takagi, Tatsuki Fukami, and Tsuyoshi Yokoi PHARMACOLOGICAL RESEARCH 28 10 2467-2476 2011/10
- Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Hiroko Hosomi, Tatsuki Fukami, Atsushi Iwamura, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 39 8 1388-1395 2011/08
- Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Tomomi Hioki, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 39 8 1345-1352 2011/08
- Estradiol and progesterone modulate halothane-induced liver injury in mice. Yasuyuki Toyoda, Taishi Miyashita, Shinya Endo, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY LETTERS 204 1 17-24 2011/07
- CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 39 5 838-846 2011/05
- IL-4 mediates dicloxacillin-induced liver injury in mice. Satonori Higuchi, Masanori Kobayashi, Yukitaka Yoshikawa, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY LETTERS 200 3 139-145 2011/02
- Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Shin-ichi Yokota, Eriko Higashi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima BIOCHEMICAL PHARMACOLOGY 81 2 289-294 2011/01
- Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Katsuhiko Mizuno, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi ARCHIVES OF TOXICOLOGY 85 3 199-207 2011/05
- Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through ERK signaling pathway. Katsuhiko Mizuno, Tatsuki Fukami, Yasuyuki Toyoda, Miki Nakajima, and Tsuyoshi Yokoi LIFE SCIENCES 87 537-544 2010/10
- In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Tatsuki Fukami, Shiori Takahashi, Nao Nakagawa, Taiga Maruichi, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 38 12 2173-2178 2010/12
- Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. Masanori Kobayashi, Satonori Higuchi, Katsuhiko Mizuno, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY 275 50-57 2010/09
- Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Akinobu Watanabe, Tatsuki Fukami, Shiori Takahashi, Yuki Kobayashi, Nao Nakagawa, Miki Nakajima, and Tsuyoshi Yokoi DRUG METABOLISM AND DISPOSITION 38 9 1532-1537 2010/09
- Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Tatsuki Fukami, Miki Nakajima, Isao Matsumoto, Yoh Zen, Makoto Oda, and Tsuyoshi Yokoi Cancer Science 101 4 1024-1028 2010/04
- MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle. Shingo Takagi, Miki Nakajima, Katsuhiko Kida, Yu Yamaura, Tatsuki Fukami, and Tsuyoshi Yokoi JOURNAL OF BIOLOGICAL CHEMISTRY 285 7 4415-4422 2010/02
- An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells. Hiroko Hosomi, Sho Akai, Keiichi Minami, Yukitaka Yoshikawa, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY IN VITRO 24 3 1032-1038 2010/04
- Human CYP2E1 is regulated by miR-378. Takuya Mohri, Miki Nakajima, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, and Tsuyoshi Yokoi BIOCHEMICAL PHARMACOLOGY 79 7 1045-1052 2010/04
- Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). Taiga Maruichi, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi BIOCHEMICAL PHARMACOLOGY 79 2 288-295 2010/01
- Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rats. Yukitaka Yoshikawa, Mayu Morita, Hiroko Hosomi, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY 264 89-95 2009/07
- Halothane-induced liver injury is mediated by interleukin-17 in mice. Eisuke Kobayashi, Masanori Kobayashi, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGICAL SCIENCES 111 302-310 2009/07
- Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Yukitaka Yoshikawa, Hiroko Hosomi, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi TOXICOLOGY IN VITRO 23 1179-1187 2009/06
- Quantitative analysis of UGT1A and UGT2B expression levels in human livers. Izukawa Takeshi, Miki Nakajima, Ryoichi Fujiwara, Hiroyuki Yamanaka, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Shin-ichi Ikushiro, Toshiyuki Sakaki, Tsuyoshi Yokoi 37 8 1759-1768 2009/08
- Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Akinobu Watanabe, Tatsuki Fukami, Miki Nakajima, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi 37 7 1513-1520 2009/07
- Structure and characterization of human carboxylesterase1A1, 1A2, and 1A3 genes. Tatsuki Fukami, Miki Nakajima, Taiga Maruichi, Shiori Takahashi, Masataka Takamiya, Yasuhiro Aoki, Howard L McLeod, Tsuyoshi Yokoi 18 10 911-920 2008/10
- Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. Takuro Endo, Miki Nakajima, Tatsuki Fukami, Yoshiki Hara, Tomoko Hasunuma, Tsuyoshi Yokoi, Yasunori Momose 18 9 761-772 2008/09
- Human Cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Tatsuki Fukami, Miki Katoh, Hiroshi Yamazaki, Tsuyoshi Yokoi, Miki Nakajima 21 3 720-725 2008/03
- Human CYP2A6 is induced by estrogen via estrogen receptor. Eriko Higashi, Tatsuki Fukami, Masahiro Itoh, Satoru Kyo, Masaki Inoue, Tsuyoshi Yokoi, Miki Nakajima 35 10 1935-1941 2007/10
- A novel duplication type of CYP2A6 gene in African-American population. Tatsuki Fukami, Miki Nakajima, Hiroyuki Yamanaka, Yasunari Fukushima, Howard L McLeod, Tsuyoshi Yokoi 35 4 515-520 2007/04
- CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin and theophylline. Tatsuki Fukami, Miki Nakajima, Haruko Sakai, Miki Katoh, Tsuyoshi Yokoi 35 3 335-339 2007/03
- Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four world populations. Miki Nakajima, Tatsuki Fukami, Hiroyuki Yamanaka, Eriko Higashi, Haruko Sakai, Ryoko Yoshida, Jun-Tack Kwon, Howard L McLeod, Tsuyoshi Yokoi 80 3 282-297 2006/03
- CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Miki Nakajima, Masahiro Itoh, Haruko Sakai, Tatsuki Fukami, Miki Katoh, Hiroyuki Yamanaka, Fred F Kadlubar, Susumu Imaoka, Yoshihiko Funae, Tsuyoshi Yokoi 119 11 2520-2526 2006/11
- CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A. Tatsuki Fukami, Miki Nakajima, Haruko Sakai, Howard L McLeod, Tsuyoshi Yokoi 6 6 401-412 2006/11
- Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. Miki Nakajima, Masahiro Itoh, Hiroyuki Yamanaka, Tatsuki Fukami, Shogo Tokudome, Yasuhiko Yamamoto, Hiroshi Yamamoto, Tsuyoshi Yokoi 46 3 337-344 2006/03
- CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Hiroyuki Yamanaka, Miki Nakajima, Tatsuki Fukami, Haruko Sakai, Akiko Nakamura, Miki Katoh, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi 33 12 1811-1818 2005/12
- A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Tatsuki Fukami, Miki Nakajima, Eriko Higashi, Hiroyuki Yaamanaka, Howard L McLeod, Tsuyoshi Yokoi 70 5 801-808 2005/09
- Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Tatsuki Fukami, Miki Nakajima, Eriko Higashi, Hiroyuki Yamanaka, Haruko Sakai, Howard L McLeod, Tsuyoshi Yokoi 33 8 1202-1210 2005/08
- A novel polymorphism of CYP2A6 gene CYP2A6*17 has amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Tatsuki Fukami, Miki Nakajima, Ryoko Yoshida, Yuki Tsuchiya, Yuto Fujiki, Miki Katoh, Howard L McLeod, Tsuyoshi Yokoi 76 6 519-527 2004/12
- Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Hiroyuki Yamanaka, Miki Nakajima, Kiyoko Nishimura, Ryoko Yoshida, Tatsuki Fukami, Miki Katoh, Tsuyoshi Yokoi 22 5 419-425 2004/08
- Novel human CYP2A6 alleles confound gene deletion analysis. Miki Nakajima, Ryoko Yoshida, Tatsuki Fukami, Howard l McLeod, Tsuyoshi Yokoi 569 1-3 75-81 2004/07
- SLC35B1 significantly contributes to the uptake of UDPGA into the endoplasmic reticulum for glucuronidation catalyzed by UDP-glucuronosyltransferases. Kyoko Ondo,Hiroshi Arakawa,Masataka Nakano,Tatsuki Fukami,Miki Nakajima Biochemical pharmacology 175 113916 2020/05
- Decrease in ADAR1 expression by exposure to cigarette smoke enhances susceptibility to oxidative stress Masashi Takizawa,Masataka Nakano,Tatsuki Fukami,Miki Nakajima Toxicology Letters 331 22 2020/10
- The N6-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression. Kyoko Ondo,Motoki Isono,Masataka Nakano,Shiori Hashiba,Tatsuki Fukami,Miki Nakajima Biochemical pharmacology 189 114402 2020/12/30
- Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models Mai Shimizu,Tatsuki Fukami,Hiroyuki Ogawa,Toshio Taniguchi,Yukihiro Nomura,Miki Nakajima Journal of Pharmaceutical Sciences 110 2 925 2021/02
- Role of human AADAC on hydrolysis of eslicarbazepine acetate and effects of AADAC genetic polymorphisms on hydrolase activity . Keiya Hirosawa,Tatsuki Fukami,Kiyomichi Tashiro,Yoshiyuki Sakai,Fumiya Kisui,Masataka Nakano,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 49 4 322 2021/01/14
- Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers Keito Amai,Tatsuki Fukami,Hiroyuki Ichida,Akiko Watanabe,Masataka Nakano,Kengo Watanabe,Miki Nakajima Drug Metabolism and Pharmacokinetics 35 6 539 2020/12
- Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor. Seiya Takemoto,Masataka Nakano,Kaori Nozaki,Tatsuki Fukami,Miki Nakajima Drug metabolism and pharmacokinetics 37 100367 2020/11/10
- Human superoxide dismutase 1 attenuates quinoneimine metabolite formation from mefenamic acid Takuo Ogiso,Tatsuki Fukami,Cheng Zhongzhe,Keigo Konishi,Masataka Nakano,Miki Nakajima Toxicology 448 152648 2021/01
- Identification of an isoform catalyzing the CoA conjugation of nonsteroidal anti-inflammatory drugs and the evaluation of the expression levels of acyl-CoA synthetases in the human liver Hiroki Hashizume,Tatsuki Fukami,Kanji Mishima,Hiroshi Arakawa,Kenji Mishiro,Yongjie Zhang,Masataka Nakano,Miki Nakajima Biochemical Pharmacology 183 114303 2021/01
- Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver. Yongjie Zhang,Rei Sato,Tatsuki Fukami,Masataka Nakano,Miki Nakajima Xenobiotica; the fate of foreign compounds in biological systems 51 12 1352 2021/11/30
- m6A modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2. Seiya Takemoto,Masataka Nakano,Tatsuki Fukami,Miki Nakajima Biochemical pharmacology 193 114766 2021/09/16
- Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. Tatsuki Fukami,Tsuyoshi Yokoi,Miki Nakajima Annual review of pharmacology and toxicology 2021/09/09
- Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase. Kaori Yasuda,Kazuki Watanabe,Tatsuki Fukami,Shimon Nakashima,Shin-Ichi Ikushiro,Miki Nakajima,Toshiyuki Sakaki Drug metabolism and pharmacokinetics 39 100397 2021/08
- Identification of miRNAs that regulate human CYP2B6 expression. Masataka Nakano,Chika Iwakami,Tatsuki Fukami,Miki Nakajima Drug metabolism and pharmacokinetics 38 100388 2021/06
- Hydrolase activities of cynomolgus monkey liver microsomes and recombinant CES1, CES2, and AADAC. Shiori Honda,Tatsuki Fukami,Takuya Tsujiguchi,Yongjie Zhang,Masataka Nakano,Miki Nakajima European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 161 105807 2021/03/17
- Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. Yoshiyuki Sakai,Tatsuki Fukami,Mai Nagaoka,Keiya Hirosawa,Hiroyuki Ichida,Rei Sato,Kohei Suzuki,Masataka Nakano,Miki Nakajima Life sciences 284 119896 2021/08/25
- Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver. Hiroyuki Ichida,Tatsuki Fukami,Keito Amai,Kohei Suzuki,Kenji Mishiro,Shiori Takano,Wataru Obuchi,Zhengyu Zhang,Akiko Watanabe,Masataka Nakano,Kengo Watanabe,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 1 17 2023/01
- NEAT1_2 and DAZAP1, paraspeckle components, interact with PXR to negatively regulate CYP3A4 induction. Rei Mitamura,Masataka Nakano,Motoki Isono,Kiamu Kurosawa,Tatsuki Fukami,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 10 1230 2023/06/22
- In vitro evaluation of the reductase activities of human AKR1C3 allelic variants. Shiori Takano,Tatsuki Fukami,Hiroyuki Ichida,Kohei Suzuki,Masataka Nakano,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 9 1188 2023/06/21
- Utility of a Systematic Approach to Selecting Candidate Prodrugs: A Case Study Using Candesartan Ester Analogues. Mai Shimizu,Tatsuki Fukami,Keisho Okura,Toshio Taniguchi,Yukihiro Nomura,Miki Nakajima Journal of pharmaceutical sciences 112 6 1671 2023/06
- Activation of Inflammation by MCF-7 Cells-Derived Small Extracellular Vesicles (sEV): Comparison of Three Different Isolation Methods of sEV. Kohei Suzuki,Masataka Nakano,Shimon Nakashima,Tatsuki Fukami,Miki Nakajima Pharmaceutical research 40 4 863 2022/08/24
- PPARα regulates the expression of human arylacetamide deacetylase involved in drug hydrolysis and lipid metabolism. Tomomi Morikawa,Tatsuki Fukami,Saki Gotoh-Saito,Masataka Nakano,Miki Nakajima Biochemical pharmacology 199 115010 2022/03/18
- Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans. Shiori Honda,Tatsuki Fukami,Keiya Hirosawa,Takuya Tsujiguchi,Yongjie Zhang,Masataka Nakano,Shotaro Uehara,Yasuhiro Uno,Hiroshi Yamazaki,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 49 9 718 2021/09
- Prediction of combination effect of quinidine on the pharmacokinetics of tipepidine using a physiologically based pharmacokinetic model. Shun Hayashi,Hiroko Kawaguchi,Takao Watanabe,Izuru Miyawaki,Tatsuki Fukami,Miki Nakajima Xenobiotica; the fate of foreign compounds in biological systems 1 2024/01/09
- Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine. Keiya Hirosawa,Hijiri Fujioka,Gaku Morinaga,Tatsuki Fukami,Naoki Ishiguro,Wataru Kishimoto,Hiroshi Nakase,Hiroyuki Mizuguchi,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 12 1569 2023/12
- Evaluation of drug-drug interactions via inhibition of hydrolases by orlistat, an anti-obesity drug. Keiya Hirosawa,Tatsuki Fukami,Masataka Nakano,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 8 1016 2023/05/03
- Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver. Shun Hayashi,Hiroko Kawaguchi,Takao Watanabe,Izuru Miyawaki,Tatsuki Fukami,Miki Nakajima Xenobiotica; the fate of foreign compounds in biological systems 53 4 241 2023/04
- Characterization of Enzymes Involved in Nintedanib Metabolism in Humans. Shimon Nakashima,Rei Sato,Tatsuki Fukami,Takashi Kudo,Shiori Hashiba,Gaku Morinaga,Masataka Nakano,Eva Ludwig-Schwellinger,Akiko Matsui,Naoki Ishiguro,Thomas Ebner,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 6 733 2023/03/16
- Evaluation of lens opacity due to inhibition of cholesterol biosynthesis using rat lens explant cultures. Taishi Miyashita,Masanori Senshu,Kanata Ibi,Hiroyuki Yamanaka,Hiroaki Nejishima,Tatsuki Fukami,Miki Nakajima Toxicology 465 153064 2022/01/15
- Development and Validation of a Proteomic Correlation Profiling Technique to Detect and Identify Enzymes Involved in Metabolism of Drugs of Concern. Takashi Kudo,Shiori Hashiba,Tatsuki Fukami,Gaku Morinaga,Kotaro Nishiyama,Hiroyuki Ichida,Keiya Hirosawa,Akiko Matsui,Naoki Ishiguro,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 51 7 824 2023/07
- Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. Mai Nagaoka,Tatsuki Fukami,Fumiya Kisui,Takuya Yamada,Yoshiyuki Sakai,Kiyomichi Tashiro,Takuo Ogiso,Keigo Konishi,Shiori Honda,Keiya Hirosawa,Masataka Nakano,Miki Nakajima Biochemical pharmacology 195 114842 2021/11/16
- Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients. Koki Katayama,Shimon Nakashima,Hiroo Ishida,Yutaro Kubota,Masataka Nakano,Tatsuki Fukami,Yasutsuna Sasaki,Ken-Ichi Fujita,Miki Nakajima Non-coding RNA research 6 3 123 2021/09
- Identification of HSD17B12 as an enzyme catalyzing drug reduction reactions through investigation of nabumetone metabolism. Hiroyuki Ichida,Tatsuki Fukami,Takashi Kudo,Kenji Mishiro,Shiori Takano,Masataka Nakano,Gaku Morinaga,Akiko Matsui,Naoki Ishiguro,Miki Nakajima Archives of biochemistry and biophysics 736 109536 2023/01/29
- Adenosine N6-methylation upregulates the expression of human CYP2B6 by altering the chromatin status. Motoki Isono,Masataka Nakano,Tatsuki Fukami,Miki Nakajima Biochemical pharmacology 205 115247 2022/09/13
- Methionine sulfoxide reductase A in human and mouse tissues is responsible for sulindac activation, making a larger contribution than the gut microbiota. Keiya Hirosawa,Tatsuki Fukami,Mai Nagaoka,Masataka Nakano,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 50 5 725 2022/03/12
- Impact of miR-222-3p-mediated downregulation of arylacetamide deacetylase on drug hydrolysis and lipid accumulation Yoshiyuki Sakai,Tatsuki Fukami,Shinsaku Tokumitsu,Masataka Nakano,Shimon Nakashima,Yuichiro Higuchi,Shotaro Uehara,Nao Yoneda,Hiroshi Suemizu,Miki Nakajima Drug Metabolism and Pharmacokinetics 101007 2024/03
- ncBAF enhances PXR-mediated transcriptional activation in the human and mouse liver. Kiamu Kurosawa,Masataka Nakano,Itsuki Yokoseki,Mai Nagaoka,Seiya Takemoto,Yoshiyuki Sakai,Kaoru Kobayashi,Yasuhiro Kazuki,Tatsuki Fukami,Miki Nakajima Biochemical pharmacology 215 115733 2023/08/03
- Quantitative evaluation of the contribution of each aldo-keto reductase and short-chain dehydrogenase/reductase isoform to reduction reactions of compounds containing a ketone group in the human liver. Hiroyuki Ichida,Tatsuki Fukami,Keito Amai,Kohei Suzuki,Kenji Mishiro,Shiori Takano,Wataru Obuchi,Zhengyu Zhang,Akiko Watanabe,Masataka Nakano,Kengo Watanabe,Miki Nakajima Drug metabolism and disposition: the biological fate of chemicals 2022/10/30
Conference Presentations
- Toxicological relevance of non-P450 enzymes: hydrolases and aldehyde oxidase(conference：12th International ISSX Meeting)(2019/07/28)
- Characterization of enzymes determining the formations of acyl-glucuronidate and acyl-CoA conjugate(conference：The 37th Annual Meeting of the Japanese Society for the Study of Xenobiotics)(2022/11/09)
- Superoxide dismutase 1 attenuates reactive quinoneimine formation from mefenamic acid in the human liver(conference：The 47th Annual Meeting of the Japanese Society of Toxicology)(2020)
- Characterization of major drug-metabolizing hydrolase: AADAC, CES1, and CES2: species differences between human and experimental animals(conference：33rd JSSX Annual Meeting and 22nd MDO)(2018/10/02)
- Roles of hydrolase and aldehyde oxidase in controlling of pharmacokinetics and drug toxicity(conference：32nd JSSX Annual Meeting)(2017/12/01)
- Significance of orphan drug-metabolizing esterases in pharmacokinetics and toxicities(conference：21st North American ISSX Meeting)(2017/09/28)
- Significance of arylacetamide deacetylase in drug metabolism and toxicity(conference：14th European ISSX Meeting)(2017/06/29)
- Recent progress in characterization of esterases in human: implications in drug development(conference：28th JSSX Annual Meeting)(2013/10/10)
Others
Arts and Fieldwork
Patent
Theme to the desired joint research
Grant-in-Aid for Scientific Research
○「薬の副作用発現に関与するヒト還元酵素の同定および機能解析」(2016-2018)
○「薬の副作用発症に関わるオーファン加水分解酵素の機能解析」(2014-2015)
○「アシルグルクロナイドを加水分解する新規薬物代謝酵素の同定および毒性学的意義」(2011-2013)
○「ヒトオーファンカルボキシルエステラーゼの薬物動態および毒性発現における関与」(2009-2011)
○「薬物代謝酵素CYP2A6の個体差および臨床意義に関する包括的研究」(2006-2008)
○「AADACによる毒性防御および生体恒常性維持に対する鉄イオン濃度制御の重要性解明」(2023-2025)
○「AADACの毒性学的および病理学的意義の解明」(2019-2021)
Competitive research funding,Contribution
Collaborative research,Consignment study
Classes (Bachelors)
○Clinical Drug Metabolism(2023)
○Clinical Drug Metabolism(2023)
○Clinical Drug Metabolism(2023)
○Clinical Drug Metabolism(2023)
○Pharmaceutical Chemistry(2023)
○Pharmaceutical Chemistry(2023)
○Toxicology(2023)
○Toxicology(2023)
○Experiments in Pharmaceutical Practice 2(2023)
○Experiments in Pharmaceutical Practice 2(2023)
○Basic Medical and Pharmaceutical Sciences Rotation Practice（Course in Pharmaceutical Sciences）Ⅶ(2023)
○Pharmaceutical Chemistry(2023)
○Introduction to Graduation Research in Pharmacy(2020)
○Experiments in Pharmaceutical Practice 2(2020)
○Laboratory Rotation 3(2020)
○Pharmaceutical Chemistry(2019)
○Experiments in Fundamental Chemistry(2019)
○Toxicology(2019)
○Clinical Drug Metabolism(2019)
○Experiments in Pharmaceutical Practice 2(2019)
○Laboratory Rotation 3(2019)
○Presentation and Debate (Freshman Seminar II)(2019)
○Experiments in Pharmaceutical Practice 2(2018)
○Pharmaceutical Chemistry(2018)
○Toxicology(2018)
○Clinical Drug Metabolism(2018)
○Laboratory Rotation 3(2018)
○Experiments in Pharmaceutical Practice 2(2017)
○Freshman Seminar I(2017)
○Clinical Drug Metabolism(2017)
○Toxicology(2017)
○Toxicology(2016)
○Clinical Drug Metabolism(2016)
○Experiments in Pharmaceutical Practice 2(2016)
Classes (Graduate Schools)
○Advanced Drug Metabolism(2023)
○Advanced Drug Metabolism(2023)
○Basic Life Sciences(2023)
○Laboratory Rotation Ｉ(2023)
○Laboratory RotationⅡ(2023)
○Laboratory RotationⅠ(2023)
○Experimental Techniques in Precision Medicine Research(2023)
○Laboratory RotationⅠ(2023)
○Laboratory Rotation I(2023)
○Laboratory Rotation I(2023)
○Advanced Drug Metabolism(2019)
○Experimental Techniques in Precision Medicine Research(2019)
○Advanced Course of ADME Studies for Drug Development(2019)
○Experimental Techniques in Precision Medicine Research(2018)
○Advanced Course of ADME Studies for Drug Development(2018)
○Drug Metabolism(2017)
○Advanced Course of ADME Studies for Drug Development(2017)
○Bone Biology(2017)
○Advanced Drug Metabolism(2017)
○Molecular Pharmaceutics(2017)
○Experimental Techniques in Precision Medicine Research(2017)
○Drug Metabolism(2016)